WO2002031128A1 - Methods of agonizing and antagonizing fabk - Google Patents
Methods of agonizing and antagonizing fabk Download PDFInfo
- Publication number
- WO2002031128A1 WO2002031128A1 PCT/US2000/027628 US0027628W WO0231128A1 WO 2002031128 A1 WO2002031128 A1 WO 2002031128A1 US 0027628 W US0027628 W US 0027628W WO 0231128 A1 WO0231128 A1 WO 0231128A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- streptococcus
- polypeptide
- fabk
- group
- seq
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 98
- 230000003042 antagnostic effect Effects 0.000 title description 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 175
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 169
- 229920001184 polypeptide Polymers 0.000 claims abstract description 166
- 239000005557 antagonist Substances 0.000 claims abstract description 55
- 239000000556 agonist Substances 0.000 claims abstract description 47
- 241000894006 Bacteria Species 0.000 claims abstract description 26
- 230000004060 metabolic process Effects 0.000 claims abstract description 6
- 208000035143 Bacterial infection Diseases 0.000 claims abstract description 4
- 208000022362 bacterial infectious disease Diseases 0.000 claims abstract description 4
- 108091033319 polynucleotide Proteins 0.000 claims description 84
- 102000040430 polynucleotide Human genes 0.000 claims description 84
- 239000002157 polynucleotide Substances 0.000 claims description 83
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 33
- 150000003384 small molecules Chemical group 0.000 claims description 24
- 150000001413 amino acids Chemical class 0.000 claims description 20
- 241000193998 Streptococcus pneumoniae Species 0.000 claims description 18
- 229940031000 streptococcus pneumoniae Drugs 0.000 claims description 18
- 241000588807 Bordetella Species 0.000 claims description 15
- 241000194017 Streptococcus Species 0.000 claims description 13
- 241000589968 Borrelia Species 0.000 claims description 10
- 241000589562 Brucella Species 0.000 claims description 10
- 241000606161 Chlamydia Species 0.000 claims description 10
- 241000186216 Corynebacterium Species 0.000 claims description 10
- 208000016604 Lyme disease Diseases 0.000 claims description 10
- 241000607768 Shigella Species 0.000 claims description 10
- 241000588724 Escherichia coli Species 0.000 claims description 8
- 238000011282 treatment Methods 0.000 claims description 8
- 208000015181 infectious disease Diseases 0.000 claims description 7
- 241000191967 Staphylococcus aureus Species 0.000 claims description 6
- 241000894007 species Species 0.000 claims description 6
- 241000589291 Acinetobacter Species 0.000 claims description 5
- 241000606750 Actinobacillus Species 0.000 claims description 5
- 241000186361 Actinobacteria <class> Species 0.000 claims description 5
- 241000607534 Aeromonas Species 0.000 claims description 5
- 241000193830 Bacillus <bacterium> Species 0.000 claims description 5
- 241000193738 Bacillus anthracis Species 0.000 claims description 5
- 241000193755 Bacillus cereus Species 0.000 claims description 5
- 241000588779 Bordetella bronchiseptica Species 0.000 claims description 5
- 241000589876 Campylobacter Species 0.000 claims description 5
- 241000588919 Citrobacter freundii Species 0.000 claims description 5
- 241000193403 Clostridium Species 0.000 claims description 5
- 241000193155 Clostridium botulinum Species 0.000 claims description 5
- 241000193468 Clostridium perfringens Species 0.000 claims description 5
- 241000193449 Clostridium tetani Species 0.000 claims description 5
- 241000588914 Enterobacter Species 0.000 claims description 5
- 241000520130 Enterococcus durans Species 0.000 claims description 5
- 241000194032 Enterococcus faecalis Species 0.000 claims description 5
- 241000588698 Erwinia Species 0.000 claims description 5
- 241000186811 Erysipelothrix Species 0.000 claims description 5
- 241000588722 Escherichia Species 0.000 claims description 5
- 241000207201 Gardnerella vaginalis Species 0.000 claims description 5
- 241000606790 Haemophilus Species 0.000 claims description 5
- 241001501603 Haemophilus aegyptius Species 0.000 claims description 5
- 241000606768 Haemophilus influenzae Species 0.000 claims description 5
- 241000606766 Haemophilus parainfluenzae Species 0.000 claims description 5
- 241000590002 Helicobacter pylori Species 0.000 claims description 5
- 241000588748 Klebsiella Species 0.000 claims description 5
- 241000589248 Legionella Species 0.000 claims description 5
- 208000007764 Legionnaires' Disease Diseases 0.000 claims description 5
- 241000589902 Leptospira Species 0.000 claims description 5
- 241000186781 Listeria Species 0.000 claims description 5
- 241000186779 Listeria monocytogenes Species 0.000 claims description 5
- 241000588621 Moraxella Species 0.000 claims description 5
- 241000186359 Mycobacterium Species 0.000 claims description 5
- 241000186366 Mycobacterium bovis Species 0.000 claims description 5
- 241000186362 Mycobacterium leprae Species 0.000 claims description 5
- 241000187479 Mycobacterium tuberculosis Species 0.000 claims description 5
- 241000187917 Mycobacterium ulcerans Species 0.000 claims description 5
- 241000204031 Mycoplasma Species 0.000 claims description 5
- 241000588653 Neisseria Species 0.000 claims description 5
- 241000588652 Neisseria gonorrhoeae Species 0.000 claims description 5
- 241000588650 Neisseria meningitidis Species 0.000 claims description 5
- 241000187654 Nocardia Species 0.000 claims description 5
- 241000588769 Proteus <enterobacteria> Species 0.000 claims description 5
- 241000588770 Proteus mirabilis Species 0.000 claims description 5
- 241000588767 Proteus vulgaris Species 0.000 claims description 5
- 241000589516 Pseudomonas Species 0.000 claims description 5
- 241000589517 Pseudomonas aeruginosa Species 0.000 claims description 5
- 241000606701 Rickettsia Species 0.000 claims description 5
- 241000606695 Rickettsia rickettsii Species 0.000 claims description 5
- 241000607142 Salmonella Species 0.000 claims description 5
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 claims description 5
- 241000607720 Serratia Species 0.000 claims description 5
- 241000607717 Serratia liquefaciens Species 0.000 claims description 5
- 241000607764 Shigella dysenteriae Species 0.000 claims description 5
- 241000607762 Shigella flexneri Species 0.000 claims description 5
- 241000605008 Spirillum Species 0.000 claims description 5
- 241000191940 Staphylococcus Species 0.000 claims description 5
- 241000191963 Staphylococcus epidermidis Species 0.000 claims description 5
- 241000193985 Streptococcus agalactiae Species 0.000 claims description 5
- 241000193996 Streptococcus pyogenes Species 0.000 claims description 5
- 241001505901 Streptococcus sp. 'group A' Species 0.000 claims description 5
- 241000193990 Streptococcus sp. 'group B' Species 0.000 claims description 5
- 241001468181 Streptococcus sp. 'group C' Species 0.000 claims description 5
- 241000194005 Streptococcus sp. 'group G' Species 0.000 claims description 5
- 241001655322 Streptomycetales Species 0.000 claims description 5
- 241000589886 Treponema Species 0.000 claims description 5
- 241000589884 Treponema pallidum Species 0.000 claims description 5
- 241000607598 Vibrio Species 0.000 claims description 5
- 241000607626 Vibrio cholerae Species 0.000 claims description 5
- 241000607734 Yersinia <bacteria> Species 0.000 claims description 5
- 241000607479 Yersinia pestis Species 0.000 claims description 5
- 241000606834 [Haemophilus] ducreyi Species 0.000 claims description 5
- 229940065181 bacillus anthracis Drugs 0.000 claims description 5
- 229940023064 escherichia coli Drugs 0.000 claims description 5
- 229940047650 haemophilus influenzae Drugs 0.000 claims description 5
- 229940037467 helicobacter pylori Drugs 0.000 claims description 5
- 229940115931 listeria monocytogenes Drugs 0.000 claims description 5
- 229940007042 proteus vulgaris Drugs 0.000 claims description 5
- 229940075118 rickettsia rickettsii Drugs 0.000 claims description 5
- 229940007046 shigella dysenteriae Drugs 0.000 claims description 5
- 229940030998 streptococcus agalactiae Drugs 0.000 claims description 5
- 241001478878 Streptobacillus Species 0.000 claims description 4
- 241000194031 Enterococcus faecium Species 0.000 claims description 3
- 229940076156 streptococcus pyogenes Drugs 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 description 91
- 239000000203 mixture Substances 0.000 description 45
- 238000003556 assay Methods 0.000 description 28
- 238000006243 chemical reaction Methods 0.000 description 28
- 230000000694 effects Effects 0.000 description 26
- 108090000790 Enzymes Proteins 0.000 description 22
- 102000004190 Enzymes Human genes 0.000 description 22
- 230000027455 binding Effects 0.000 description 22
- 210000004027 cell Anatomy 0.000 description 22
- 238000002360 preparation method Methods 0.000 description 22
- 235000001014 amino acid Nutrition 0.000 description 20
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 18
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 18
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 18
- 108090000623 proteins and genes Proteins 0.000 description 18
- 238000012216 screening Methods 0.000 description 18
- 239000007787 solid Substances 0.000 description 18
- 108020004414 DNA Proteins 0.000 description 17
- 125000003729 nucleotide group Chemical group 0.000 description 17
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 16
- 239000002773 nucleotide Substances 0.000 description 16
- 235000018102 proteins Nutrition 0.000 description 16
- 102000004169 proteins and genes Human genes 0.000 description 16
- 239000000758 substrate Substances 0.000 description 16
- 239000000243 solution Substances 0.000 description 15
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 14
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 13
- 229910001868 water Inorganic materials 0.000 description 13
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 230000004075 alteration Effects 0.000 description 12
- 150000001768 cations Chemical class 0.000 description 12
- 238000007792 addition Methods 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 230000014509 gene expression Effects 0.000 description 9
- 239000003112 inhibitor Substances 0.000 description 9
- 239000003446 ligand Substances 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 8
- 230000004048 modification Effects 0.000 description 8
- 238000012986 modification Methods 0.000 description 8
- 230000004913 activation Effects 0.000 description 7
- 239000000872 buffer Substances 0.000 description 7
- KFWWCMJSYSSPSK-PAXLJYGASA-N crotonoyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)/C=C/C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 KFWWCMJSYSSPSK-PAXLJYGASA-N 0.000 description 7
- 239000000741 silica gel Substances 0.000 description 7
- 229910002027 silica gel Inorganic materials 0.000 description 7
- 238000006467 substitution reaction Methods 0.000 description 7
- 125000000539 amino acid group Chemical group 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- -1 signal transduction Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 241000282414 Homo sapiens Species 0.000 description 5
- 238000002835 absorbance Methods 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 230000003647 oxidation Effects 0.000 description 5
- 238000007254 oxidation reaction Methods 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 238000010992 reflux Methods 0.000 description 5
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 4
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000013543 active substance Substances 0.000 description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 238000012217 deletion Methods 0.000 description 4
- 230000037430 deletion Effects 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 238000005755 formation reaction Methods 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 238000003780 insertion Methods 0.000 description 4
- 230000037431 insertion Effects 0.000 description 4
- 239000010410 layer Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 4
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 4
- 230000000069 prophylactic effect Effects 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 230000000699 topical effect Effects 0.000 description 4
- 238000005160 1H NMR spectroscopy Methods 0.000 description 3
- QZTKDVCDBIDYMD-UHFFFAOYSA-N 2,2'-[(2-amino-2-oxoethyl)imino]diacetic acid Chemical compound NC(=O)CN(CC(O)=O)CC(O)=O QZTKDVCDBIDYMD-UHFFFAOYSA-N 0.000 description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 3
- 238000005481 NMR spectroscopy Methods 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- 206010052428 Wound Diseases 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 3
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 3
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 3
- 239000001166 ammonium sulphate Substances 0.000 description 3
- 235000011130 ammonium sulphate Nutrition 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 230000000845 anti-microbial effect Effects 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- RPGACVPVPGPLHQ-VQHVLOKHSA-N benzyl (e)-3-(6-aminopyridin-3-yl)prop-2-enoate Chemical compound C1=NC(N)=CC=C1\C=C\C(=O)OCC1=CC=CC=C1 RPGACVPVPGPLHQ-VQHVLOKHSA-N 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 238000003818 flash chromatography Methods 0.000 description 3
- 108020001507 fusion proteins Proteins 0.000 description 3
- 102000037865 fusion proteins Human genes 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 238000004949 mass spectrometry Methods 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 230000004481 post-translational protein modification Effects 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- HIVQAWXDBPYNDU-UHFFFAOYSA-N (2-amino-5-bromopyridin-3-yl)methanol Chemical compound NC1=NC=C(Br)C=C1CO HIVQAWXDBPYNDU-UHFFFAOYSA-N 0.000 description 2
- FEIACFYXEWBKHU-UHFFFAOYSA-N (2-aminopyridin-3-yl)methanol Chemical compound NC1=NC=CC=C1CO FEIACFYXEWBKHU-UHFFFAOYSA-N 0.000 description 2
- RKTFOZFRTWRSLT-DUXPYHPUSA-N (e)-3-(6-aminopyridin-3-yl)prop-2-enoic acid Chemical compound NC1=CC=C(\C=C\C(O)=O)C=N1 RKTFOZFRTWRSLT-DUXPYHPUSA-N 0.000 description 2
- FKYOJCCQBUMPAM-OWOJBTEDSA-N (e)-3-[6-amino-5-(hydroxymethyl)pyridin-3-yl]prop-2-enoic acid Chemical compound NC1=NC=C(\C=C\C(O)=O)C=C1CO FKYOJCCQBUMPAM-OWOJBTEDSA-N 0.000 description 2
- LBGKZBBSLPBVEU-UHFFFAOYSA-N 1-(1h-inden-1-yl)-n-methylmethanamine;hydrochloride Chemical compound Cl.C1=CC=C2C(CNC)C=CC2=C1 LBGKZBBSLPBVEU-UHFFFAOYSA-N 0.000 description 2
- WGOLHUGPTDEKCF-UHFFFAOYSA-N 5-bromopyridin-2-amine Chemical compound NC1=CC=C(Br)C=N1 WGOLHUGPTDEKCF-UHFFFAOYSA-N 0.000 description 2
- 230000005730 ADP ribosylation Effects 0.000 description 2
- 208000031729 Bacteremia Diseases 0.000 description 2
- 108091006146 Channels Proteins 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 201000009906 Meningitis Diseases 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- 241000235070 Saccharomyces Species 0.000 description 2
- 238000012300 Sequence Analysis Methods 0.000 description 2
- 108020004566 Transfer RNA Proteins 0.000 description 2
- 206010048038 Wound infection Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- PXXJHWLDUBFPOL-UHFFFAOYSA-N benzamidine Chemical compound NC(=N)C1=CC=CC=C1 PXXJHWLDUBFPOL-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- OWMVSZAMULFTJU-UHFFFAOYSA-N bis-tris Chemical compound OCCN(CCO)C(CO)(CO)CO OWMVSZAMULFTJU-UHFFFAOYSA-N 0.000 description 2
- 239000007975 buffered saline Substances 0.000 description 2
- 239000013592 cell lysate Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000004590 computer program Methods 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- QQXQAEWRSVZPJM-UHFFFAOYSA-N ethyl 1h-indole-2-carboxylate Chemical compound C1=CC=C2NC(C(=O)OCC)=CC2=C1 QQXQAEWRSVZPJM-UHFFFAOYSA-N 0.000 description 2
- 235000019439 ethyl acetate Nutrition 0.000 description 2
- 230000006251 gamma-carboxylation Effects 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 229920000140 heteropolymer Polymers 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- 230000033444 hydroxylation Effects 0.000 description 2
- 238000005805 hydroxylation reaction Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- FLWMSHOXYOXNOW-UHFFFAOYSA-N n-methyl-n-[(3-methyl-1h-inden-2-yl)methyl]prop-2-enamide Chemical compound C1=CC=C2CC(CN(C)C(=O)C=C)=C(C)C2=C1 FLWMSHOXYOXNOW-UHFFFAOYSA-N 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 239000006225 natural substrate Substances 0.000 description 2
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 230000001323 posttranslational effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- FVSKHRXBFJPNKK-UHFFFAOYSA-N propionitrile Chemical compound CCC#N FVSKHRXBFJPNKK-UHFFFAOYSA-N 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 238000010188 recombinant method Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000000967 suction filtration Methods 0.000 description 2
- 230000019635 sulfation Effects 0.000 description 2
- 238000005670 sulfation reaction Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000007910 systemic administration Methods 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 1
- CHRJZRDFSQHIFI-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;styrene Chemical compound C=CC1=CC=CC=C1.C=CC1=CC=CC=C1C=C CHRJZRDFSQHIFI-UHFFFAOYSA-N 0.000 description 1
- KPIVDNYJNOPGBE-UHFFFAOYSA-N 2-aminonicotinic acid Chemical compound NC1=NC=CC=C1C(O)=O KPIVDNYJNOPGBE-UHFFFAOYSA-N 0.000 description 1
- 101150098072 20 gene Proteins 0.000 description 1
- LNVWRBNPXCUYJI-UHFFFAOYSA-N 3,5-dimethyl-1h-pyrazol-4-amine Chemical compound CC1=NNC(C)=C1N LNVWRBNPXCUYJI-UHFFFAOYSA-N 0.000 description 1
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 101710198510 Enoyl-[acyl-carrier-protein] reductase [NADH] Proteins 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 108010057573 Flavoproteins Proteins 0.000 description 1
- 102000003983 Flavoproteins Human genes 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 108060003393 Granulin Proteins 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108010085220 Multiprotein Complexes Proteins 0.000 description 1
- 102000007474 Multiprotein Complexes Human genes 0.000 description 1
- 101001068640 Nicotiana tabacum Basic form of pathogenesis-related protein 1 Proteins 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 206010033078 Otitis media Diseases 0.000 description 1
- 208000006588 Pleural Empyema Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 239000012564 Q sepharose fast flow resin Substances 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 1
- XEFQLINVKFYRCS-UHFFFAOYSA-N Triclosan Chemical compound OC1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1Cl XEFQLINVKFYRCS-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- HFBMWMNUJJDEQZ-UHFFFAOYSA-N acryloyl chloride Chemical compound ClC(=O)C=C HFBMWMNUJJDEQZ-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000008484 agonism Effects 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 241000617156 archaeon Species 0.000 description 1
- 230000010516 arginylation Effects 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 238000003287 bathing Methods 0.000 description 1
- URZGHGQTYAJMIN-VOTSOKGWSA-N benzyl (e)-3-[6-amino-5-(hydroxymethyl)pyridin-3-yl]prop-2-enoate Chemical compound C1=C(CO)C(N)=NC=C1\C=C\C(=O)OCC1=CC=CC=C1 URZGHGQTYAJMIN-VOTSOKGWSA-N 0.000 description 1
- GCTPMLUUWLLESL-UHFFFAOYSA-N benzyl prop-2-enoate Chemical compound C=CC(=O)OCC1=CC=CC=C1 GCTPMLUUWLLESL-UHFFFAOYSA-N 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 229940093761 bile salts Drugs 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 238000012875 competitive assay Methods 0.000 description 1
- 230000006957 competitive inhibition Effects 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000017858 demethylation Effects 0.000 description 1
- 238000010520 demethylation reaction Methods 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000007877 drug screening Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000003221 ear drop Substances 0.000 description 1
- 229940047652 ear drops Drugs 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 206010014665 endocarditis Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 125000004050 enoyl group Chemical group 0.000 description 1
- 230000009088 enzymatic function Effects 0.000 description 1
- FRLLPWADCHCBBY-UHFFFAOYSA-N ethyl 1-methylindole-2-carboxylate Chemical compound C1=CC=C2N(C)C(C(=O)OCC)=CC2=C1 FRLLPWADCHCBBY-UHFFFAOYSA-N 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 239000003885 eye ointment Substances 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000002875 fluorescence polarization Methods 0.000 description 1
- 230000022244 formylation Effects 0.000 description 1
- 238000006170 formylation reaction Methods 0.000 description 1
- 231100000221 frame shift mutation induction Toxicity 0.000 description 1
- 230000037433 frameshift Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 150000003278 haem Chemical group 0.000 description 1
- 210000003709 heart valve Anatomy 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000012188 high-throughput screening assay Methods 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 244000052637 human pathogen Species 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000026045 iodination Effects 0.000 description 1
- 238000006192 iodination reaction Methods 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 238000000816 matrix-assisted laser desorption--ionisation Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 229940051866 mouthwash Drugs 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 230000007498 myristoylation Effects 0.000 description 1
- MIEPSGVCFRDTDU-UHFFFAOYSA-N n,1-dimethylindole-2-carboxamide Chemical compound C1=CC=C2N(C)C(C(=O)NC)=CC2=C1 MIEPSGVCFRDTDU-UHFFFAOYSA-N 0.000 description 1
- QSEWWKLGOWVVGC-UHFFFAOYSA-N n-methyl-1-(2-methyl-1h-indol-3-yl)methanamine Chemical group C1=CC=C2C(CNC)=C(C)NC2=C1 QSEWWKLGOWVVGC-UHFFFAOYSA-N 0.000 description 1
- FNWONYFQJPIDCL-UHFFFAOYSA-N n-methyl-1-(3-methyl-1h-inden-2-yl)methanamine;hydrochloride Chemical compound Cl.C1=CC=C2CC(CNC)=C(C)C2=C1 FNWONYFQJPIDCL-UHFFFAOYSA-N 0.000 description 1
- 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 description 1
- 239000003883 ointment base Substances 0.000 description 1
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 1
- 229940055577 oleyl alcohol Drugs 0.000 description 1
- 229940046166 oligodeoxynucleotide Drugs 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 230000000399 orthopedic effect Effects 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000010287 polarization Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000013823 prenylation Effects 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 229940043131 pyroglutamate Drugs 0.000 description 1
- 230000006340 racemization Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 201000009890 sinusitis Diseases 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000759 toxicological effect Toxicity 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 229960003500 triclosan Drugs 0.000 description 1
- 238000010798 ubiquitination Methods 0.000 description 1
- 230000034512 ubiquitination Effects 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
- A61K39/092—Streptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
- C07K14/3156—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci from Streptococcus pneumoniae (Pneumococcus)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- This invention relates to methods of agonizing or antagonizing polynucleotides and polypeptides of the Fab family, as well as their variants, herein referred to as "FabK,” “FabK polynucleotide(s),” and “FabK polypeptide(s),” as the case may be.
- Triclosan is FabK.
- This enzyme involved in fatty acid biosynthesis, has been recently reported from Streptococcus pneumoniae, a well-known human pathogen (Heath, et al. Nature 406: 145 (2000)). The specific activity of the enzyme under the published conditions was 64 +/- 4 nmol min "1 , too low to efficiently screen for compounds that modulate the activity of the enzyme, such as inhibitors (Heath, et al. Nature 406: 145 (2000)).
- the present invention solves this problem by providing a method for screening for FabK agonists and antagonists, wherein FabK activity is sufficient to perform efficient compound screening.
- Heath teaches that organisms expressing FabK will be refractory to Fabl inhibitors, and that bacteria possessing both targets will require a combination of inhibitors to block growth (Heath, et al.
- the present invention provides methods of screening for compounds that inhibit both enzymes, as well as the use of such compounds as antimicrobial compounds.
- the present invention provides, among other things, methods are also provided for the treatment of bacterial infection comprising the step of contacting an individual with an antagonist or agonist of a FabK polypeptide.
- the invention also provides a method for modulating the metabolism of bacteria comprising the step of contacting said bacteria with an antagonist or agonist of a FabK polypeptide.
- said FabK polypeptide selected from the group consisting of: (i) an isolated polypeptide comprising an amino acid having at least 95% identity 0 to the amino acid sequence of SEQ ID NO:2 over the entire length of SEQ ID NO:2; (ii) an isolated polypeptide comprising the amino acid sequence of SEQ ID NO: 2, (iii) an isolated polypeptide that is the amino acid sequence of SEQ ID NO: 2, and (iv) a polypeptide that is encoded by a recombinant polynucleotide comprising the polynucleotide sequence of SEQ ID NO: 1.
- said antagonist is a small molecule. Still further methods are provided wherein said small molecule has the structure or
- Formula I or a homologue, stereoisomer, or a pharmaceutically accepable derivative thereof.
- a method wherein said small molecule has the structure or Formula II, or a homologue, or stereoisomer, or pharmaceutically accepable derivative thereof is also provided by the invention.
- a method is also provided wherein said bacteria is or said infection is caused by or associated with a bacteria selected from the group consisting of: a member of the genus Streptococcus, Staphylococcus, Bordetella, Corynebacterium, Mycobacterium, Neisseria, Haemophilus, Actinomycetes, Streptomycetes, Nocardia, Enterobacter, Yersinia, Fancisella, Pasturella, Moraxella, Acinetobacter, Erysipelothrix, Branhamella, Actinobacillus,
- Streptobacillus Listeria, Calymmatobacterium, Brucella, Bacillus, Clostridium, Treponema, Escherichia, Salmonella, Kleibsiella, Vibrio, Proteus, Erwinia, Borrelia, Leptospira, Spirillum, Campylobacter, Shigella, Legionella, Pseudomonas, Aeromonas, Rickettsia, Chlamydia, Borrelia and Mycoplasma, and further including, but not limited to, a member of the species or group, Group A Streptococcus, Group B Streptococcus, Group C Streptococcus, Group D
- Streptococcus Group G Streptococcus, Streptococcus pneumoniae, Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus faecalis, Streptococcus faeciutn, Streptococcus durans, Neisseria gonorrheae, Neisseria meningitidis, Staphylococcus aureus, Staphylococcus epidermidis, Corynebacterium diptheriae, Gardnerella vaginalis, Mycobacterium tuberculosis, Mycobacterium bovis, Mycobacterium ulcerans, Mycobacterium leprae, Actinomyctes israelii, Listeria monocytogenes, Bordetella pertusis, Bordatella parapertusis, Bordetella bronchiseptica, Escherichia coli, Shigella dysenteriae, Haemophilus influenzae
- a preferred method is provided wherein said modulating metabolism is inhibiting growth of said bacteria or killing said bacteria.
- the invention relates to methods using FabK polypeptides and polynucleotides as described in greater detail below.
- the invention relates to methods using polypeptides and polynucleotides of a FabK of Streptococcus pneumoniae.
- the invention relates especially to methods using FabK having a nucleotide and amino acid sequences set out in Table 1 as SEQ ID NO:l and SEQ ID NO:2 respectively.
- the start codon in SEQ ID NO: 1 begins with nucleotide 1 and the stop codon ends with nucleotide 975.
- sequences recited in the Sequence Listing below as "DNA” represent an exemplification of the invention, since those of ordinary skill will recognize that such sequences can be usefully employed in polynucleotides in general, including ribopolynucleotides.
- a deposit comprising a Streptococcus pneumoniae 0100993 strain has been deposited with the National Collections of Industrial and Marine Bacteria Ltd. (herein "NC B"), 23 St. Machar Drive, Aberdeen AB2 IRY, Scotland on 11 April 1996 and assigned deposit number 40794. The deposit was described as Streptococcus pneumoniae 0100993 on deposit. On 17 April 1996 a Streptococcus pneumoniae 0100993 DNA library in E. coli was similarly deposited with the NQMB and assigned deposit number 40800.
- the Streptococcus pneumoniae strain deposit is referred to herein as "the deposited strain” or as "the DNA of the deposited strain.”
- the deposited strain comprises a full length FabK gene.
- the sequence of the polynucleotides comprised in the deposited strain, as well as the amino acid sequence of any polypeptide encoded thereby, are controlling in the event of any conflict with any description of sequences herein.
- the deposit of the deposited strain has been made under the terms of the Budapest Treaty on the International Recognition of the Deposit of Micro-organisms for Purposes of Patent Procedure.
- the deposited strain will be irrevocably and without restriction or condition released to the public upon the issuance of a patent.
- the deposited strain is provided merely as convenience to those of skill in the art and is not an admission that a deposit is required for enablement, such as that required under 35 U.S.C. ⁇ 112.
- a license may be required to make, use or sell the deposited strain, and compounds derived therefrom, and no such license is hereby granted.
- an isolated nucleic acid molecule encoding a mature polypeptide expressible by the Streptococcus pneumoniae 0100993 strain, which polypeptide is comprised in the deposited strain.
- FabK polynucleotide sequences in the deposited strain such as DNA and RNA, and amino acid sequences encoded thereby.
- FabK polypeptide and polynucleotide sequences isolated from the deposited strain are also provided by the invention.
- Polypeptides FabK polypeptide of the invention is substantially phylogenetically related to other
- FabK polypeptides of Streptococcus pneumoniae referred to herein as "FabK” and “FabK polypeptides” as well as biologically, therapeutically or clinically useful variants thereof, and compositions comprising the same, useful in such methods.
- the present invention further provides methods using an isolated polypeptide that: (a) comprises or consists of an amino acid sequence that has at least 95% identity, most preferably at least 97-99% or exact identity, to that of SEQ ID NO:2 over the entire length of SEQ ID NO:2; (b) a polypeptide encoded by an isolated polynucleotide comprising or consisting of a polynucleotide sequence that has at least 95% identity, even more preferably at least 97-99% or exact identity to SEQ ID NO:l over the entire length of SEQ ID NO:l; (c) a polypeptide encoded by an isolated polynucleotide comprising or consisting of a polynucleotide sequence encoding a polypeptide that has at least 95% identity, even more preferably at least 97-99% or exact identity, to
- polypeptides of the methods of the invention include, for example, a polypeptide of Table 1 [SEQ ID NO:2] (in particular a mature polypeptide) as well as polypeptides and fragments, particularly those that has a biological activity of FabK, and also those that have at least 95% identity to a polypeptide of Table 1 [SEQ ID NO:2] and also include portions of such polypeptides with such portion of the polypeptide generally comprising at least 30 amino acids and more preferably at least 50 amino acids, particularly those portions possessing an activity of a wild type FabK.
- the invention also includes methods using a polypeptide consisting of or comprising a polypeptide of the formula: X-(R 1 ) m -(R 2 )-(R 3 ) n -Y wherein, at the amino terminus, X is hydrogen, a metal or any other moiety described herein for modified polypeptides, and at the carboxyl terminus, Y is hydrogen, a metal or any other moiety described herein for modified polypeptides, R j and R3 are any amino acid residue or modified amino acid residue, m is an integer between 1 and 1000 or zero, n is an integer between 1 and 1000 or zero, and R 2 is an amino acid sequence of the invention, particularly an amino acid sequence selected from Table 1 or modified forms thereof.
- R 2 is oriented so that its amino terminal amino acid residue is at the left, covalently bound to R
- Any stretch of amino acid residues denoted by either Rj or R3, where m and/or n is greater than 1, may be either a heteropolymer or a homopolymer, preferably a heteropolymer.
- Other preferred embodiments of the invention are provided where m is an integer between 1 and 50, 100 or 500, and n is an integer between 1 and 50, 100, or 500.
- polypeptide used is derived from Streptococcus pneumoniae; however, it may also be obtained from other organisms of the same taxonomic genus. Methods are also provided using polypeptides from organisms of the same taxonomic family or order, among other organisms as described elsewhere herein.
- a fragment is a variant polypeptide having an amino acid sequence that is entirely the same as part but not all of any amino acid sequence of any polypeptide used in the methods of the invention.
- fragments may be "free-standing,” or comprised within a larger polypeptide of which they form a part or region, most preferably as a single continuous region in a single larger polypeptide.
- Preferred fragments used in the methods of the invention include, for example, truncation polypeptides having a portion of an amino acid sequence of Table 1 [SEQ ID NO:2], or of variants thereof, such as a continuous series of residues that includes an amino- and/or carboxyl-terminal amino acid sequence, particularly those possessing an enzymatic function of wild type FabK.
- Polypeptides and polynucleotides described herein may be used to assess the binding or other effects of small molecule substrates and ligands in, for example, cells, cell-free preparations, chemical libraries, and natural product mixtures. These substrates and ligands may be natural substrates and ligands or may be structural or functional mimetics. See, e.g., Coligan et al, Current Protocols in Immunology 1(2): Chapter 5 (1991). Polypeptides and polynucleotides described herein are responsible for many biological functions, including many disease states, in particular the Diseases herein mentioned, among others.
- the present invention provides for a method of screening candidate compounds to identify those that agonize (e.g., stimulate) or that antagonize (e.g., inhibit) a function of a polypeptide or polynucleotide of the invention, as well as related polypeptides and polynucleotides.
- agonists or antagonists may be employed for therapeutic and prophylactic purposes against such Diseases as herein mentioned.
- Compounds (herein also "candidate compound(s)”) may be identified or selected from a variety of sources, for example, cells, cell-free preparations, known or newly synthesized compounds, chemical libraries, and natural product mixtures.
- Such compounds such as agonists and antagonists, so-identified may be natural or modified substrates, ligands, receptors, enzymes, etc., as the case may be, of FabK polypeptides and polynucleotides; or may be structural or functional mimetics thereof (see Coligan et al, Current Protocols in Immunology l(2):Chapter 5 (1991)).
- Antagonists of the invention include, among others, small organic molecules, peptides, polypeptides and antibodies that bind to a polynucleotide and/or polypeptide of the invention and thereby inhibit or extinguish its activity or expression.
- Antagonists also may be a small organic molecule, a peptide, a polypeptide, a closely related protein or antibody that binds the same sites on a binding molecule without inducing FabK-induced activities.
- Such antagonists preferably prevent the action or expression of FabK polypeptides and/or polynucleotides by excluding FabK polypeptides and/or polynucleotides from binding.
- Preferred embodiments of the invention comprise compounds of Formula I and Formula II, as well as homologues and stereoisomers thereof. These compounds are a representative set of compounds useful in the methods of the invention.
- compositions comprising an antagonist or agonist of FabK polypeptide, particularly a small molecule, especially a small molecule having the structure or Formula I or Formula II, or is a homologue, stereoisomer, or a pharmaceutically accepable derivative thereof either compound.
- FabK polypeptide selected from the group consisting of: (i) an isolated polypeptide comprising an amino acid having at least 95% identity to the amino acid sequence of SEQ ID NO:2 over the entire length of SEQ ID NO:2; (ii) an isolated polypeptide comprising the amino acid sequence of SEQ ID NO:2, (iii) an isolated polypeptide that is the amino acid sequence of SEQ ID NO:2, and (iv) a polypeptide that is encoded by a recombinant polynucleotide comprising the polynucleotide sequence of SEQ ID NO:l, are also preferred.
- antagonists or agonists of the invention include compounds that alter the binding of a cation to FabK, or alter an activity of a cation on FabK, particularly a monovalent cation. It is preferred that such antagonists inhibit such binding or lower such activity.
- Preferred agonists and antagonists of the invention are those that also agonize or antagonize an activity of Fabl.
- An agonist of Fabl may act as an antagonist of FabK and visa versa, or such compounds may agonize or antagonize both Fabl and FabK.
- the invention provides that these agonists and antagonists, when used as antimicrobial compounds, will be less likely to generate resistant mutants than for compounds that only act on a single target. This is a significant and surprising discovery in view of the teachings of Heath indicating that organisms that express FabK will be refractory to Fabl inhibitors, and that bacteria possessing both targets will require a combination of inhibitors to block growth (Heath, et al. Nature 406: 145 (2000)).
- the compounds of Formulae I and II provide representative examples of compounds that antagonize both FabK and Fabl.
- Antagonists of the invention further include small molecules that bind to and occupy the binding site of a FabK polypeptide thereby preventing binding to cellular binding molecules, such that normal biological activity is prevented.
- small molecules include but are not limited to small organic molecules, peptides or peptide-like molecules.
- Other antagonists include antisense molecules (see Okano, J. Neurochem. 56: 560 (1991); OLIGODEOXYNUCLEOTIDES AS ANTISENSE INHIBITORS OF GENE EXPRESSION, CRC Press, Boca Raton, FL (1988), for a description of these molecules).
- Candidate compounds of the invention that are small molecules preferably have a molecular weight below 2,000 daltons, more preferably between 300 and 1,000 daltons, and most preferably between 400 and 700 daltons. It is particularly preferred that these small molecules are organic molecules.
- the invention provides a method for treatment of bacterial infection comprising the step of contacting an individual with an antagonist or agonist of or a FabK polypeptide, particularly a FabK polypeptide selected from the group consisting of: (i) an isolated polypeptide comprising an amino acid having at least 95% identity to the amino acid sequence of SEQ ID NO: 2 over the entire length of SEQ ID NO:2; (ii) an isolated polypeptide comprising the amino acid sequence of SEQ ID NO:2, (iii) an isolated polypeptide that is the amino acid sequence of SEQ ID NO:2, and (iv) a polypeptide that is encoded by a recombinant polynucleotide comprising the polynucleotide sequence of SEQ ID NO:l.
- the compounds of the invention may also be used in a method for modulating the metabolism of bacteria comprising the step of contacting said bacteria with an antagonist or agonist of or a FabK polypeptide.
- said antagonist is a small molecule. Still further methods are provided wherein said small molecule has the structure or Formula I, or is a homologue, stereoisomer, or a pharmaceutically accepable derivative thereof.
- a method wherein said small molecule has the structure or Formula II, or is a homologue, or stereoisomer, or pharmaceutically accepable derivative thereof is also provided by the invention.
- a method is also provided wherein said infection is caused by or associated with a bacteria selected from the group consisting of: a member of the genus Streptococcus, Staphylococcus, Bordetella, Corynebacterium, Mycobacterium, Neisseria, Haemophilus, Actinomycetes, Streptomycetes, Nocardia, Enterobacter, Yersinia, Fancisella, Pasturella, Moraxella, Acinetobacter, Erysipelothrix, Branhamella, Actinobacillus, Streptobacillus, Listeria, Calymmatobacterium, Brucella, Bacillus, Clostridium, Treponema, Escherichia, Salmonella, Kleibsiella, Vibrio, Proteus, Er
- the contacting step in any of the methods of the invention may be performed in many ways that will be readily apparent to the skilled artisan. However, it is preferred that the contacting step is a provision of a composition comprising a FabK agonist or antagonist to a human patient in need of such composition or directly to bacteria in culture medium or buffer.
- compositions comprising a FabK agonist or antagonist may be administered in any effective, convenient manner including, for instance, administration by topical, oral, anal, vaginal, intravenous, intraperitoneal, intramuscular, subcutaneous, intranasal or intradermal routes among others.
- the screening methods of the invention may simply measure the binding of a candidate compound to a FabK polypeptide or polynucleotide, or to cells or membranes bearing a FabK polypeptide or polynucleotide, or a fusion protein of a FabK polypeptide by means of a label directly or indirectly associated with a candidate compound.
- the screening method may involve competition with a labeled competitor.
- these screening methods may test whether a candidate compound results in a signal generated by activation or inhibition of a FabK polypeptide or polynucleotide, using detection systems appropriate to the cells comprising a FabK polypeptide or polynucleotide.
- Inhibitors of activation are generally assayed in the presence of a known agonist and the effect on activation by the agonist by the presence of the candidate compound is observed.
- Constitutively active polypeptide and/or constitutively expressed polypeptides and polynucleotides may be employed in screening methods for inverse agonists, in the absence of an agonist or antagonist, by testing whether the candidate compound results in inhibition of activation of the polypeptide or polynucleotide, as the case may be.
- the screening methods may simply comprise the steps of mixing a candidate compound with a solution comprising a polypeptide or polynucleotide of the present invention, to form a mixture, measuring FabK polypeptide and/or polynucleotide activity in the mixture, and comparing the FabK polypeptide and/or polynucleotide activity of the mixture to a standard.
- Fusion proteins such as those made from Fc portion and FabK polypeptide, as herein described, can also be used for high-throughput screening assays to identify antagonists of the polypeptide of the present invention, as well as of phylogenetically and and/or functionally related polypeptides (see D. Bennett et al., J Mol Recognition, 8:52-58 (1995); and K. Johanson et al., J Biol Chem, 270(16):9459-9471 (1995)).
- polypeptides and antibodies that bind to and/or interact with a polypeptide of the present invention may also be used to configure screening methods for detecting the effect of added compounds on the production of mRNA and/or polypeptide in cells.
- an ELISA assay may be constructed for measuring secreted or cell associated levels of polypeptide using monoclonal and polyclonal antibodies by standard methods known in the art. This can be used to discover agents that may inhibit or enhance the production of polypeptide (also called antagonist or agonist, respectively) from suitably manipulated cells or tissues.
- the invention also provides a method of screening candidate compounds to identify those that stimulate or inhibit an activity of FabK polypeptides or polynucleotides, particularly those compounds that are bacteriostatic and/or bactericidal.
- the method of screening may involve high-throughput techniques. For example, to screen for agonists or antagonists, a synthetic reaction mix, a cellular compartment, such as a membrane, cell envelope or cell wall, or a preparation of any thereof, comprising FabK polypeptide and a labeled substrate or ligand of such polypeptide is incubated in the absence or the presence of a candidate molecule that may be a FabK agonist or antagonist.
- a candidate molecule to agonize or antagonize the FabK polypeptide is reflected in decreased binding of the labeled ligand or decreased production of product from such substrate.
- Molecules that bind gratuitously, i.e., without inducing the effects of FabK polypeptide are most likely to be good antagonists.
- Molecules that bind well and, as the case may be, increase the rate of product production from substrate, increase signal transduction, or increase chemical channel activity are agonists. Detection of the rate or level of, as the case may be, production of product from substrate, signal transduction, or chemical channel activity may be enhanced by using a reporter system.
- Reporter systems that may be useful in this regard include but are not limited to colorimetric, labeled substrate converted into product, a reporter gene that is responsive to changes in FabK polynucleotide or polypeptide activity, and binding assays known in the art.
- Polypeptides of the invention may be used to identify membrane bound or soluble receptors, if any, for such polypeptide, through standard receptor binding techniques known in the art. These techniques include, but are not limited to, ligand binding and crosslinking assays in which the polypeptide is labeled with a radioactive isotope (for instance, l ⁇ I), chemically modified (for instance, biotinylated), or fused to a peptide sequence suitable for detection or purification, and incubated with a source of the putative receptor (e.g., cells, cell membranes, cell supernatants, tissue extracts, bodily materials). Other methods include biophysical techniques such as surface plasmon resonance and spectroscopy. These screening methods may also be used to identify agonists and antagonists of the polypeptide that compete with the binding of the polypeptide to its receptor(s), if any. Standard methods for conducting such assays are well understood in the art.
- a radioactive isotope for instance, l ⁇ I
- the fluorescence polarization value for a fluorescently-tagged molecule depends on the rotational correlation time or tumbling rate. Protein complexes, such as formed by FabK polypeptide associating with a candidate compound, labeled to comprise a fluorescently-labeled molecule will have higher polarization values than a fluorescently labeled FabK protein not bound to a candidate compound. It is preferred that this method be used to characterize small molecules that bind FabK.
- FabK polypeptide can be coupled to a sensor chip at low site density such that covalently bound molecules will be monomeric.
- Solution protein can then passed over the FabK polypeptide-coated surface and specific binding can be detected in real-time by monitoring the change in resonance angle caused by a change in local refractive index. This technique can be used to characterize the effect of small molecules on kinetic rates and equilibrium binding constants for FabK polypeptide self- association as well as an association of FabK polypeptide and another polypeptide or small molecule.
- a FabK polypeptide and/or polynucleotide of the invention comprising: contacting a FabK polypeptide and/or polynucleotide of the invention with a compound to be screened under conditions to permit binding to or other interaction between the compound and the FabK polypeptide and/or polynucleotide to assess the binding to or other interaction with the compound, such binding or interaction preferably being associated with a second component capable of providing a detectable signal in response to the binding or interaction of the polypeptide and/or polynucleotide with the compound; and determining whether the compound binds to or otherwise interacts with and activates or inhibits an activity or expression of the FabK polypeptide and/or polynucleotide by detecting the presence or absence of a signal generated from the binding or interaction of the compound with the FabK polypeptide and/or polynucleo
- an assay for FabK agonists or antagonists is a competitive assay that combines FabK and a potential agonist or antagonist with FabK-binding molecules, recombinant FabK binding molecules, natural substrates or ligands, or substrate or ligand mimetics, under appropriate conditions for a competitive inhibition assay.
- FabK can be labeled, such as by radioactivity or a colorimetric compound, such that the number of FabK molecules bound to a binding molecule or converted to product can be determined accurately to assess the effectiveness of the potential agonist antagonist.
- a further assay is provided whereby compounds that are agonists or antagonists of FabK are assayed to determine whether they are also agonists or antagonists of Fabl, and visa versa.
- an assay mixture comprises both Fabl and FabK.
- FabK catalyses the reduction of enoyl-ACPs with the concomitant oxidation of NADH. Screening methods based on this reaction are preferred embodiments herein. Such methods may comprise the step of detecting reduction of crotonoyl-ACP to butyryl-ACP.
- Detection may be monitored, for example, by following the change in absorbance at a particular wavelength in the light spectrum, preferably at 340 nm, or by any other means of assaying NADH oxidation. Assays may be carried out, for example, in Costar 3696 half- area plates, preferably at a final assay volume of 150 ul on a Spectramax platereader.
- Preferred substrates used in the methods of the invention are NADH, NADPH, an NADH analogue, crotonoyl ACP and crotonyl CoA.
- FabK enzyme in 100 mM N-[2- acetamido]-2 iminodiacetic acid (ADA), pH 6.5, 100 mM NH 4 C1, 4% glycerol at 30°C, folllowed by an incubation step for 30 minutes after the addition of FabK.
- ADA acetamido-2 iminodiacetic acid
- This reaction may be monitored at 340 nm, among other wavelengths.
- a particularly preferred embodiment is a method comprising the step of providing monovalent cations to an assay mixture. This step enhances the activity of FabK enzyme. Any cation, or any compound that increases or enhances the activity of the enzyme, may be used in this method; however, NH 4 + is preferred, and a concentration of 100 mM is most- preferred. Adding cations to the assay mixture is vastly superior to assaying in the absence of added cation. The activation in the reaction may be about 300-fold over the reaction with no monovalent cations added, such as in a cell-lysate assay without additional cations. Using the assay methods of the invention, compounds may be tested for inhibition of FabK.
- the assay is performed using an assay volume of between 5 and 200 ul of candidate compound, more preferably 10 and 50 ul of candidate compound, and most preferably 30 ul.
- Preferred methods also utilize NADH, crotonoyl ACP and crotonyl CoA in the assay mixture.
- the final concentration in the assay mixture is between 10 uM and 50 uM crotonoyl ACP, but is most preferably 25 uM crotonoyl ACP; is between 20 uM and 100 uM NADH, but is most preferably 50 uM NADH; and is between 0.25 nM and 1.75 nM FabK enzyme, but is most preferably 1.25 nM FabK enzyme.
- the assay mixtures are incubated at between 20 °C and 40 °C, preferably between 28 °C to 37°C, and most preferably at about 30°C. Preferred incubation times range between 30 seconds and 1 hour, are more preferably between 3 minutes and 30 minutes, and are most preferably about 4 or 5 minutes.
- positive controls without added candidate compound, are used in a reaction well to gauge the degree of agonism or antagonism of a candidate compound.
- Negative controls, without enzyme may also be used.
- compositions comprising a FabK agonist or antagonist for administration to a cell or to a multicellular organism.
- compositions comprising an agonist or antagonist discussed herein or their agonists or antagonists.
- Agonists or antagonists of the invention may be employed in combination with a non-sterile or sterile carrier or carriers for use with cells, tissues or organisms, such as a pharmaceutical carrier suitable for administration to an individual.
- Such compositions comprise, for instance, a media additive or a therapeutically effective amount of an agonist or antagonist of the invention and a pharmaceutically acceptable carrier or excipient.
- Such carriers may include, but are not limited to, saline, buffered saline, dextrose, water, glycerol, ethanol and combinations thereof.
- the formulation should suit the mode of administration.
- the invention further relates to diagnostic and pharmaceutical packs and kits comprising one or more containers filled with one or more of the ingredients of the aforementioned compositions of the invention.
- Agonists or antagonists and other compounds of the invention may be employed alone or in conjunction with other compounds, such as therapeutic compounds.
- FabK agonist or antagonists of the invention may be employed alone or in conjunction with other compounds, such as bacterial efflux pump inhibitor compounds or antibiotic compounds, particularly Fabl agonists of antagonists.
- the pharmaceutical compositions may be administered in any effective, convenient manner including, for instance, administration by topical, oral, anal, vaginal, intravenous, intraperitoneal, intramuscular, subcutaneous, intranasal or intradermal routes among others.
- the active agent may be administered to an individual as an injectable composition, for example as a sterile aqueous dispersion, preferably isotonic.
- the composition may be formulated for topical application for example in the form of ointments, creams, lotions, eye ointments, eye drops, ear drops, mouthwash, impregnated dressings and sutures and aerosols, and may contain appropriate conventional additives, including, for example, preservatives, solvents to assist drug penetration, and emollients in ointments and creams.
- Such topical formulations may also contain compatible conventional carriers, for example cream or ointment bases, and ethanol or oleyl alcohol for lotions.
- Such carriers may constitute from about 1% to about 98% by weight of the formulation; more usually they will constitute up to about 80% by weight of the formulation.
- the present invention provides for pharmaceutical compositions comprising a therapeutically effective amount of a FabK agonist or antagonist, such as the soluble form of a compound of the present invention, an agonist or antagonist peptide or small molecule compound, in combination with a pharmaceutically acceptable carrier or excipient.
- a pharmaceutically acceptable carrier or excipient include, but are not limited to, saline, buffered saline, dextrose, water, glycerol, ethanol, and combinations thereof.
- the invention further relates to pharmaceutical packs and kits comprising one or more containers filled with one or more of the ingredients of the aforementioned compositions of the invention.
- composition will be adapted to the route of administration, for instance by a systemic or an oral route.
- Preferred forms of systemic administration include injection, typically by intravenous injection. Other injection routes, such as subcutaneous, intramuscular, or intraperitoneal, can be used.
- Alternative means for systemic administration include transmucosal and transdermal administration using penetrants such as bile salts or fusidic acids or other detergents.
- penetrants such as bile salts or fusidic acids or other detergents.
- oral administration may also be possible. Administration of these compounds may also be topical and/or localized, in the form of salves, pastes, gels, and the like.
- the daily dosage level of the active agent will be from 0.01 mg/kg to 10 mg/kg, typically around 1 mg/kg.
- the physician in any event will determine the actual dosage that will be most suitable for an individual and will vary with the age, weight and response of the particular individual.
- the above dosages are exemplary of the average case. There can, of course, be individual instances where higher or lower dosage ranges are merited, and such are within the scope of this invention.
- the dosage is selected to modulate metabolism of the bacteria in such a way as to inhibit or stop growth of said bacteria or by killing said bacteria. The skilled artisan may identify this amount as provided herein as well as by using other methods known in the art, e.g. by the application MIC tests.
- In-dwelling devices include surgical implants, prosthetic devices and catheters, i.e., devices that are introduced to the body of an individual and remain in position for an extended time.
- Such devices include, for example, artificial joints, heart valves, pacemakers, vascular grafts, vascular catheters, cerebrospinal fluid shunts, urinary catheters, continuous ambulatory peritoneal dialysis (CAPD) catheters.
- CAPD continuous ambulatory peritoneal dialysis
- composition of the invention may be administered by injection to achieve a systemic effect against relevant bacteria shortly before insertion of an in-dwelling device. Treatment may be continued after surgery during the in-body time of the device.
- composition could also be used to broaden perioperative cover for any surgical technique to prevent bacterial wound infections, especially wound infections from an organism described herein.
- Many orthopedic surgeons consider that humans with prosthetic joints should be considered for antibiotic prophylaxis before dental treatment that could produce a bacteremia. Late deep infection is a serious complication sometimes leading to loss of the prosthetic joint and is accompanied by significant morbidity and mortality. It may therefore be possible to extend the use of the active agent as a replacement for prophylactic antibiotics in this situation.
- compositions of this invention may be used generally as a wound treatment agent to prevent adhesion of bacteria to matrix proteins exposed in wound tissue and for prophylactic use in dental treatment as an alternative to, or in conjunction with, antibiotic prophylaxis.
- the composition of the invention may be used to bathe an indwelling device immediately before insertion.
- the active agent will preferably be present at a concentration of 1 ⁇ g/ml to lOmg/ml for bathing of wounds or indwelling devices.
- a vaccine composition is conveniently in injectable form. Conventional adjuvants may be employed to enhance the immune response.
- a suitable unit dose for vaccination is 0.5-5 microgram/kg of antigen, and such dose is preferably administered 1-3 times and with an interval of 1-3 weeks. With the indicated dose range, no adverse toxicological effects will be observed with the compounds of the invention that would preclude their administration to suitable individuals.
- Disease(s) means any disease caused by or related to infection by an organism, particularly Staphylococcus aureus and Streptococcus pneumoniae, including, for example, otitis media, conjunctivitis, pneumonia, bacteremia, meningitis, sinusitis, pleural empyema and endocarditis, and most particularly meningitis, such as for example infection of cerebrospinal fluid.
- Identity is a relationship between two or more polypeptide sequences or two or more polynucleotide sequences, as the case may be, as determined by comparing the sequences.
- identity also means the degree of sequence relatedness between polypeptide or polynucleotide sequences, as the case may be, as determined by the match between strings of such sequences.
- Identity can be readily calculated by known methods, including but not limited to those described in (Computational Molecular Biology, Lesk, A.M., ed., Oxford University Press, New York, 1988; Biocomputing: Informatics and Genome Projects, Smith, D.W., ed., Academic Press, New York, 1993; Computer Analysis of Sequence Data, Part I, Griffin, A.M., and Griffin, H.G., eds., Humana Press, New Jersey, 1994; Sequence Analysis in Molecular Biology, von Heinje, G., Academic Press, 1987; and Sequence Analysis Primer, Gribskov, M.
- the BLAST X program is publicly available from NCBI and other sources (BI ⁇ ST Manual, Altschul, S., et al, NCBI NLM NIH Bethesda, MD 20894;
- Parameters for polypeptide sequence comparison include the following: Algorithm:
- Parameters for polynucleotide comparison include the following: Algorithm:
- Polynucleotide embodiments further include an isolated polynucleotide comprising a polynucleotide sequence having at least a 95, 97 or 100% identity to the reference sequence of SEQ ID NO:l, wherein said polynucleotide sequence may be identical to the reference sequence of SEQ ID NO: 1 or may include up to a certain integer number of nucleotide alterations as compared to the reference sequence, wherein said alterations are selected from the group consisting of at least one nucleotide deletion, substitution, including transition and transversion, or insertion, and wherein said alterations may occur at the 5' or 3' terminal positions of the reference nucleotide sequence or anywhere between those terminal positions, interspersed either individually among the nucleotides in the reference sequence or in one or more contiguous groups within the reference sequence, and wherein said number of nucleotide alterations is determined by multiplying the total number of nucleotides in SEQ ID NO:l by the integer defining the percent identity divided by 100 and then subtracting
- n n is the number of nucleotide alterations
- x n is the total number of nucleotides in SEQ ID NO:l
- y is 0.95 for 95%, 0.97 for 97% or 1.00 for 100%
- • is the symbol for the multiplication operator, and wherein any non-integer product of x n and y is rounded down to the nearest integer prior to subtracting it from x n .
- Alterations of a polynucleotide sequence encoding the polypeptide of SEQ ID NO:2 may create nonsense, missense or frameshift mutations in this coding sequence and thereby alter the polypeptide encoded by the polynucleotide following such alterations.
- Polypeptide embodiments further include an isolated polypeptide comprising a polypeptide having at least a 95, 97 or 100% identity to a polypeptide reference sequence of SEQ ID NO:2, wherein said polypeptide sequence may be identical to the reference sequence of SEQ ED NO:2 or may include up to a certain integer number of amino acid alterations as compared to the reference sequence, wherein said alterations are selected from the group consisting of at least one amino acid deletion, substitution, including conservative and non- conservative substitution, or insertion, and wherein said alterations may occur at the amino- or carboxy-terminal positions of the reference polypeptide sequence or anywhere between those terminal positions, interspersed either individually among the amino acids in the reference sequence or in one or more contiguous groups within the reference sequence, and wherein said number of amino acid alterations is determined by multiplying the total number of amino acids in SEQ ID NO:2 by the integer defining the percent identity divided by 100 and then subtracting that product from said total number of amino acids in SEQ ID NO:2, or:
- n a is the number of amino acid alterations
- x a is the total number of amino acids in SEQ ID NO:2
- y is 0.95 for 95%, 0.97 for 97% or 1.00 for 100%
- • is the symbol for the multiplication operator, and wherein any non-integer product of x a and y is rounded down to the nearest integer prior to subtracting it from x a .
- isolated means altered “by the hand of man” from its natural state, i.e., if it occurs in nature, it has been changed or removed from its original environment, or both.
- a polynucleotide or a polypeptide naturally present in a living organism is not “isolated,” but the same polynucleotide or polypeptide separated from the coexisting materials of its natural state is “isolated”, as the term is employed herein.
- a polynucleotide or polypeptide that is introduced into an organism by transformation, genetic manipulation or by any other recombinant method is "isolated” even if it is still present in said organism, which organism may be living or non-living.
- Organism(s) means a (i) prokaryote, including but not limited to, a member of the genus Streptococcus, Staphylococcus, Bordetella, Corynebacterium, Mycobacterium, Neisseria, Haemophilus, Actinomycetes, Streptomycetes, Nocardia, Enterobacter, Yersinia, Fancisella, Pasturella, Moraxella, Acinetobacter, Erysipelothrix, Branhamella, Actinobacillus, Streptobacillus, Listeria, Calymmatobacterium, Brucella, Bacillus, Clostridium, Treponema, Escherichia, Salmonella, Kleibsiella, Vibrio, Proteus, Erwinia, Borrelia, Leptospira, Spirillum, Campylobacter, Shigella, Legionella, Pseudomonas, Aeromonas
- Polynucleotide(s) generally refers to any polyribonucleotide or polydeoxyribonucleotide, that may be unmodified RNA or DNA or modified RNA or DNA.
- Polynucleotide(s) include, without limitation, single- and double-stranded DNA, DNA that is a mixture of single- and double-stranded regions or single-, double- and triple-stranded regions, single- and double-stranded RNA, and RNA that is mixture of single- and double-stranded regions, hybrid molecules comprising DNA and RNA that may be single-stranded or, more typically, double-stranded, or triple-stranded regions, or a mixture of single- and double- stranded regions.
- polynucleotide refers to triple-stranded regions comprising RNA or DNA or both RNA and DNA.
- the strands in such regions may be from the same molecule or from different molecules.
- the regions may include all of one or more of the molecules, but more typically involve only a region of some of the molecules.
- One of the molecules of a triple-helical region often is an oligonucleotide.
- the term "polynucleotide(s)” also includes DNAs or RNAs as described above that comprise one or more modified bases. Thus, DNAs or RNAs with backbones modified for stability or for other reasons are "polynucleotide(s)" as that term is intended herein.
- DNAs or RNAs comprising unusual bases, such as inosine, or modified bases, such as tritylated bases, to name just two examples are polynucleotides as the term is used herein. It will be appreciated that a great variety of modifications have been made to DNA and RNA that serve many useful purposes known to those of skill in the art.
- the term "polynucleotide(s)" as it is employed herein embraces such chemically, enzymatically or metabolically modified forms of polynucleotides, as well as the chemical forms of DNA and RNA characteristic of viruses and cells, including, for example, simple and complex cells. "Polynucleotide(s)” also embraces short polynucleotides often referred to as oligonucleotide(s).
- Polypeptide(s) refers to any peptide or protein comprising two or more amino acids joined to each other by peptide bonds or modified peptide bonds.
- Polypeptide(s) refers to both short chains, commonly referred to as peptides, oligopeptides and oligomers and to longer chains generally referred to as proteins. Polypeptides may comprise amino acids other than the 20 gene encoded amino acids.
- Polypeptide(s) include those modified either by natural processes, such as processing and other post-translational modifications, but also by chemical modification techniques. Such modifications are well described in basic texts and in more detailed monographs, as well as in a voluminous research literature, and they are well known to those of skill in the art.
- a given polypeptide may comprise many types of modifications. Modifications can occur anywhere in a polypeptide, including the peptide backbone, the amino acid side-chains, and the amino or carboxyl termini.
- Modifications include, for example, acetylation, acylation, ADP-ribosylation, amidation, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of phosphotidylinositol, cross-linking, cyclization, disulfide bond formation, demethylation, formation of covalent cross-links, formation of cysteine, formation of pyroglutamate, formylation, gamma-carboxylation, GPI anchor formation, hydroxylation, iodination, methylation, myristoylation, oxidation, proteolytic processing, phosphorylation, prenylation, racemization, glycosylation, lipid attachment, sulfation, gamma- carboxylation of glutamic acid residues, hydroxylation and ADP-ribosylation, selenoylation,
- Polypeptides may be branched or cyclic, with or without branching. Cyclic, branched and branched circular polypeptides may result from post-translational natural processes and may be made by entirely synthetic methods, as well.
- Recombinant expression system(s) refers to expression systems or portions thereof or polynucleotides of the invention introduced or transformed into a host cell or host cell lysate for the production of the polynucleotides and polypeptides of the invention.
- Variant(s) is a polynucleotide or polypeptide that differs from a reference polynucleotide or polypeptide respectively, but retains essential properties.
- a typical variant of a polynucleotide differs in nucleotide sequence from another, reference polynucleotide. Changes in the nucleotide sequence of the variant may or may not alter the amino acid sequence of a polypeptide encoded by the reference polynucleotide. Nucleotide changes may result in amino acid substitutions, additions, deletions, fusion proteins and truncations in the polypeptide encoded by the reference sequence, as discussed below.
- a typical variant of a polypeptide differs in amino acid sequence from another, reference polypeptide. Generally, differences are limited so that the sequences of the reference polypeptide and the variant are closely similar overall and, in many regions, identical.
- a variant and reference polypeptide may differ in amino acid sequence by one or more substitutions, additions, deletions in any combination.
- a substituted or inserted amino acid residue may or may not be one encoded by the genetic code.
- the present invention also includes include variants of each of the polypeptides of the invention, that is polypeptides that vary from the referents by conservative amino acid substitutions, whereby a residue is substituted by another with like characteristics.
- variants are among Ala, Val, Leu and He; among Ser and Thr; among the acidic residues Asp and Glu; among Asn and Gin; and among the basic residues Lys and Arg; or aromatic residues Phe and Tyr.
- Particularly preferred are variants in which several, 5-10, 1-5, 1-3, 1-2 or 1 amino acids are substituted, deleted, or added in any combination.
- a variant of a polynucleotide or polypeptide may be a naturally occurring such as an allelic variant, or it may be a variant that is not known to occur naturally.
- Non-naturally occurring variants of polynucleotides and polypeptides may be made by mutagenesis techniques, by direct synthesis, and by other recombinant methods known to skilled artisans.
- EXAMPLES The examples below are carried out using standard techniques, that are well known and routine to those of skill in the art, except where otherwise described in detail. The examples are illustrative, but do not limit the invention.
- the S. pneumoniae fabK, enoyl-ACP reductase gene was PCR amplified from S. pneumoniae strain 0100993.
- the forward and reverse primer sequences were
- Intact FabK is expressed as 25% total cell protein of which 80% is soluble when induced with 0.1 mM IPTG at 37°C for three hours.
- Example 2 Purification of S.pneumoniae FabK
- Fractions containing FabK were identified by their absorbance at A460 and by their FabK activity and pooled. 1.5 M ammonium sulphate was added to the pooled fractions and these were then loaded onto a Hi-load Phenyl sepharose (16/10) column (Pharmacia) equilibrated in 50 mM Tris pH 7.5, 1 mM PMSF, 1 mM Benzamidine, 1 mM DTT, 1.5 M ammonium sulphate. Proteins were eluted with a gradient of ammonium sulphate (1.5 to 0 M) over 200 ml. Fractions containing FabK were identified as above and pooled.
- the pooled fractions were buffer exchanged into 100 mM Tris, pH 7.5, 2 mM DTT and glycerol was then added to 50%.
- the protein was stored at -20°C. It is preferred that the enzyme be stored with NH 4 C1, which has been found to stabilize the enzyme.
- the identity of the protein was confirmed by N-terrninal sequencing and MALDI mass spectrometry.
- the optical spectrum of the protein was characteristic of flavoproteins, showing an absorbance in the 450nm region.
- the FAD cofactor was removed by denaturation of the protein and quantified.
- the ratio of FAD:protein was shown to be approximately 1:1.
- Example 4 Assaying the activity of FabK FabK catalyses the reduction of enoyl-ACPs with the concommitant oxidation of NADH.
- Crotonoyl- ACP can be prepared as described below. The reduction of crotonoyl- ACP to butyryl-ACP can be monitored by following the change in absorbance at 340 nm as NADH is oxidised. Assays were carried out in Costar 3696 half-area plates in a final assay volume of
- FabK was found to be activated by monovalent cations. The greatest activation was found to be with NH 4 + at 100 mM, which activated the reaction about 300-fold over the reaction with no monovalent cations.
- compounds can be tested for inhibition of FabK.
- 30 ul of a candidate compounds is added to a well of the plate.
- 30 ul of a 250 uM stock of NADH is then added to the well.
- 60 ul of a 67.5 uM stock of Crotonoyl ACP is added to the well.
- the plate is incubated at 30°C for 5 min.
- 30 ul of a 6.25 nM stock of enzyme is then added to the well (also preincubated at 30°C) to initiate the reaction.
- the plate is then monitored at A340nm for 30 min at 30°C.
- Positive controls are reactions without compound.
- Negative controls are reactions without enzyme and without compound.
- Final concentrations in the assay mixture are 25 uM crotonoyl ACP, 50 uM NADH, 1.25 nM enzyme.
- Crotonoyl -ACP was synthesised using S. pneumoniae ACP synthase to catalyse the addition of a crotonoyl group from crotonoyl CoA to E.coli apo-acyl carrier protein (ACP).
- reaction mixture was loaded at 10 mL/min onto a Q-Sepharose FF column (5 x 16 cm) pre-equilibrated with 20 mM Bis-Tris, pH 6.8. Crotonoyl-ACP was eluted over 2200 ml using a 0.2M-0.6M NaCl gradient at a flow rate of 20 ml/min. Fractions were monitored by mass spectrometry for identity and purity. The appropriate fractions were pooled and concentrated using a YM-3 membrane.
- Crotonoyl-ACP can be prepared as described in patent applications numbered PCT/US00/12104 and EP1997000306506. The reduction of enoyl-ACPs can be monitored by following the change in absorbance at 340 nm as NADH is oxidised. Enoyl ACPs (eg crotonoyl- ACP) can be replaced by enoyl-CoAs (eg crotonoyl-CoA)
- This assaying can also be performed using crotonyl CoA, NADPH or an NADH analogue as a substrate, or using a substrate suitable for FabK, such as those described above.
- compounds can be tested for inhibition of Fabl.
- 30 ul of a candidate compounds is added to a well of the plate.
- 30 ul of a 250 uM stock of NADH is then added to the well.
- 60 ul of a 67.5 uM stock of Crotonoyl ACP is added to the well.
- Mass spectra were obtained using electrospray (ES) ionization techniques. Elemental analyses were performed by Quantitative Technologies Inc., Whitehouse, NJ. Melting points were obtained on a Thomas-Hoover melting point apparatus and are uncorrected. All temperatures are reported in degrees Celsius.
- Analtech Silica Gel GF and E. Merck Silica Gel 60 F-254 thin layer plates were used for thin layer chromatography. Flash chromatography was carried out on E. Merck Kieselgel 60 (230-400 mesh) silica gel.
- ODS refers to an octadecylsilyl derivatized silica gel chromatographic support.
- YMC ODS-AQ® is an ODS chromatographic support and is a registered trademark of YMC Co. Ltd., Kyoto, Japan.
- PRP-1® is a polymeric (styrene-divinylbenzene) chromatographic support, and is a registered trademark of Hamilton Co., Reno, Nevada.
- Celite® is a filter aid composed of acid- washed diatomaceous silica, and is a registered trademark of Manville Corp., Denver, Colorado.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002424987A CA2424987A1 (en) | 2000-10-06 | 2000-10-06 | Methods of agonizing and antagonizing fabk |
AU2000277557A AU2000277557A1 (en) | 2000-10-06 | 2000-10-06 | Methods of agonizing and antagonizing fabk |
EP00967340A EP1330515A4 (en) | 2000-10-06 | 2000-10-06 | Methods of agonizing and antagonizing fabk |
PCT/US2000/027628 WO2002031128A1 (en) | 2000-10-06 | 2000-10-06 | Methods of agonizing and antagonizing fabk |
US10/407,028 US7048926B2 (en) | 2000-10-06 | 2003-04-04 | Methods of agonizing and antagonizing FabK |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US2000/027628 WO2002031128A1 (en) | 2000-10-06 | 2000-10-06 | Methods of agonizing and antagonizing fabk |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/407,028 Continuation US7048926B2 (en) | 2000-10-06 | 2003-04-04 | Methods of agonizing and antagonizing FabK |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2002031128A1 true WO2002031128A1 (en) | 2002-04-18 |
Family
ID=21741855
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2000/027628 WO2002031128A1 (en) | 2000-10-06 | 2000-10-06 | Methods of agonizing and antagonizing fabk |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1330515A4 (en) |
AU (1) | AU2000277557A1 (en) |
CA (1) | CA2424987A1 (en) |
WO (1) | WO2002031128A1 (en) |
Cited By (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6753172B1 (en) | 1996-08-28 | 2004-06-22 | Affinium Pharmaceuticals, Inc. | FabI |
US6821746B2 (en) | 2000-10-06 | 2004-11-23 | Affinium Pharmaceuticals, Inc. | Methods of screening for FabK antagonists and agonists |
US6951729B1 (en) | 1999-10-27 | 2005-10-04 | Affinium Pharmaceuticals, Inc. | High throughput screening method for biological agents affecting fatty acid biosynthesis |
WO2006008660A2 (en) * | 2004-07-20 | 2006-01-26 | Affinium Pharmaceuticals, Inc. | Streptococcus pneumoniae enoyl- (acyl-carrier-protein) reductase (fabk) |
US7033795B2 (en) | 2000-10-06 | 2006-04-25 | Affinium Pharmaceuticals, Inc. | FabK variant |
US7048926B2 (en) | 2000-10-06 | 2006-05-23 | Affinium Pharmaceuticals, Inc. | Methods of agonizing and antagonizing FabK |
US7056697B2 (en) | 2000-10-06 | 2006-06-06 | Affinium Pharmaceuticals, Inc. | FabK variant |
JP2006523207A (en) * | 2003-03-17 | 2006-10-12 | アフィナム ファーマシューティカルズ,インコーポレーテッド | Composition comprising a plurality of antibiotics and method of using the same |
US7176299B2 (en) | 1996-02-20 | 2007-02-13 | Affinium Pharmaceuticals, Inc. | Compounds |
US7250285B2 (en) | 1996-08-16 | 2007-07-31 | Affinium Pharmaceuticals, Inc. | Purified polypeptides from Streptococcus pneumoniae |
US7799547B2 (en) | 2003-07-11 | 2010-09-21 | Affinium Pharmaceuticals, Inc. | Purified polypeptides from Staphylococcus aureus |
US7884124B2 (en) | 2006-06-30 | 2011-02-08 | Sepracor Inc. | Fluoro-substituted inhibitors of D-amino acid oxidase |
US7893098B2 (en) | 2003-12-29 | 2011-02-22 | Sepracor Inc. | Pyrrole and pyrazole DAAO inhibitors |
US7902252B2 (en) | 2007-01-18 | 2011-03-08 | Sepracor, Inc. | Inhibitors of D-amino acid oxidase |
US8053603B2 (en) | 2006-01-06 | 2011-11-08 | Sunovion Pharmaceuticals Inc. | Tetralone-based monoamine reuptake inhibitors |
US8097760B2 (en) | 2006-03-31 | 2012-01-17 | Sunovion Pharmacuticals Inc. | Preparation of chiral amides and amines |
KR101299399B1 (en) * | 2004-06-04 | 2013-08-22 | 아피늄 파마슈티컬스, 인크. | Therapeutic Agents, and Methods of Making and Using the Same |
US8669291B2 (en) | 2007-05-31 | 2014-03-11 | Sunovion Pharmaceuticals Inc. | Phenyl substituted cycloalkylamines as monoamine reuptake inhibitors |
US8877975B2 (en) | 2006-01-06 | 2014-11-04 | Sunovion Pharmaceuticals Inc. | Cycloalkylamines as monoamine reuptake inhibitors |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998024475A1 (en) * | 1996-12-05 | 1998-06-11 | Astra Aktiebolag | Nucleic acid and amino acid sequences relating to helicobacter pylori and vaccine compositions thereof |
WO1998026072A1 (en) * | 1996-12-13 | 1998-06-18 | Eli Lilly And Company | Streptococcus pneumoniae dna sequences |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR025976A1 (en) * | 1999-10-08 | 2002-12-26 | Affinium Pharm Inc | FAB INHIBITORS I. |
-
2000
- 2000-10-06 CA CA002424987A patent/CA2424987A1/en not_active Abandoned
- 2000-10-06 EP EP00967340A patent/EP1330515A4/en not_active Withdrawn
- 2000-10-06 WO PCT/US2000/027628 patent/WO2002031128A1/en active Application Filing
- 2000-10-06 AU AU2000277557A patent/AU2000277557A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998024475A1 (en) * | 1996-12-05 | 1998-06-11 | Astra Aktiebolag | Nucleic acid and amino acid sequences relating to helicobacter pylori and vaccine compositions thereof |
WO1998026072A1 (en) * | 1996-12-13 | 1998-06-18 | Eli Lilly And Company | Streptococcus pneumoniae dna sequences |
Non-Patent Citations (4)
Title |
---|
COHEN J.S. ET AL.: "Oligodeoxynucleotides as antisense inbitors of gene expression", PROGRESS IN NUCLEIC ACID RESEARCH AND MOLECULAR BIOLOGY, vol. 42, June 1992 (1992-06-01), pages 79 - 126, XP002937978 * |
HEATH R.J. ET AL.: "A triclosan-resistant bacterial enzyme", NATURE, vol. 406, 13 July 2000 (2000-07-13), pages 145 - 146, XP000993256 * |
REVILL W.P. ET AL.: "Purification of a malonyltransferase from streptomyces coelicolor A3(2) and analysis of its genetic determinant", JOURNAL OF BACTERIOLOGY, vol. 177, no. 14, July 1995 (1995-07-01), pages 3947 - 3952, XP002937977 * |
See also references of EP1330515A4 * |
Cited By (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7422749B2 (en) | 1996-02-20 | 2008-09-09 | Affinium Pharmaceuticals, Inc. | Compounds |
US7176299B2 (en) | 1996-02-20 | 2007-02-13 | Affinium Pharmaceuticals, Inc. | Compounds |
US7250285B2 (en) | 1996-08-16 | 2007-07-31 | Affinium Pharmaceuticals, Inc. | Purified polypeptides from Streptococcus pneumoniae |
US6753172B1 (en) | 1996-08-28 | 2004-06-22 | Affinium Pharmaceuticals, Inc. | FabI |
US6995254B1 (en) | 1996-08-28 | 2006-02-07 | Affinium Pharmaceuticals, Inc. | Polynucleotide encoding the enoyl-acyl carrier protein reductase of Staphylococcus aureus, FAB I |
US6951729B1 (en) | 1999-10-27 | 2005-10-04 | Affinium Pharmaceuticals, Inc. | High throughput screening method for biological agents affecting fatty acid biosynthesis |
US7048926B2 (en) | 2000-10-06 | 2006-05-23 | Affinium Pharmaceuticals, Inc. | Methods of agonizing and antagonizing FabK |
US7033795B2 (en) | 2000-10-06 | 2006-04-25 | Affinium Pharmaceuticals, Inc. | FabK variant |
US7056697B2 (en) | 2000-10-06 | 2006-06-06 | Affinium Pharmaceuticals, Inc. | FabK variant |
US6821746B2 (en) | 2000-10-06 | 2004-11-23 | Affinium Pharmaceuticals, Inc. | Methods of screening for FabK antagonists and agonists |
JP2006523207A (en) * | 2003-03-17 | 2006-10-12 | アフィナム ファーマシューティカルズ,インコーポレーテッド | Composition comprising a plurality of antibiotics and method of using the same |
JP4880448B2 (en) * | 2003-03-17 | 2012-02-22 | アフィナム ファーマシューティカルズ,インコーポレーテッド | Composition comprising a plurality of antibiotics and method of using the same |
US7799547B2 (en) | 2003-07-11 | 2010-09-21 | Affinium Pharmaceuticals, Inc. | Purified polypeptides from Staphylococcus aureus |
US7893098B2 (en) | 2003-12-29 | 2011-02-22 | Sepracor Inc. | Pyrrole and pyrazole DAAO inhibitors |
KR101299399B1 (en) * | 2004-06-04 | 2013-08-22 | 아피늄 파마슈티컬스, 인크. | Therapeutic Agents, and Methods of Making and Using the Same |
WO2006008660A2 (en) * | 2004-07-20 | 2006-01-26 | Affinium Pharmaceuticals, Inc. | Streptococcus pneumoniae enoyl- (acyl-carrier-protein) reductase (fabk) |
WO2006008660A3 (en) * | 2004-07-20 | 2006-10-26 | Affinium Pharm Inc | Streptococcus pneumoniae enoyl- (acyl-carrier-protein) reductase (fabk) |
US8053603B2 (en) | 2006-01-06 | 2011-11-08 | Sunovion Pharmaceuticals Inc. | Tetralone-based monoamine reuptake inhibitors |
US8877975B2 (en) | 2006-01-06 | 2014-11-04 | Sunovion Pharmaceuticals Inc. | Cycloalkylamines as monoamine reuptake inhibitors |
US9868718B2 (en) | 2006-01-06 | 2018-01-16 | Sunovion Pharmaceuticals Inc. | Cycloalkylamines as monoamine reuptake inhibitors |
US10562878B2 (en) | 2006-01-06 | 2020-02-18 | Sunovion Pharamceuticals Inc. | Cycloalkylamines as monoamine reuptake inhibitors |
US8097760B2 (en) | 2006-03-31 | 2012-01-17 | Sunovion Pharmacuticals Inc. | Preparation of chiral amides and amines |
US7884124B2 (en) | 2006-06-30 | 2011-02-08 | Sepracor Inc. | Fluoro-substituted inhibitors of D-amino acid oxidase |
US7902252B2 (en) | 2007-01-18 | 2011-03-08 | Sepracor, Inc. | Inhibitors of D-amino acid oxidase |
US8669291B2 (en) | 2007-05-31 | 2014-03-11 | Sunovion Pharmaceuticals Inc. | Phenyl substituted cycloalkylamines as monoamine reuptake inhibitors |
US9586888B2 (en) | 2007-05-31 | 2017-03-07 | Sunovion Pharmaceuticals Inc. | Phenyl substituted cycloalkylamines as monoamine reuptake inhibitors |
Also Published As
Publication number | Publication date |
---|---|
AU2000277557A1 (en) | 2002-04-22 |
EP1330515A4 (en) | 2005-12-07 |
CA2424987A1 (en) | 2002-04-18 |
EP1330515A1 (en) | 2003-07-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7048926B2 (en) | Methods of agonizing and antagonizing FabK | |
WO2002031128A1 (en) | Methods of agonizing and antagonizing fabk | |
US6197300B1 (en) | ftsZ | |
US6660520B2 (en) | Nrde | |
US6251629B1 (en) | ABC transporter | |
US6211161B1 (en) | UDP-N-acetylmuramoyl-l-alanine:D-glutamate ligase (MURD) of staphylococcus aureus | |
US6110723A (en) | Yfii pseudouridine synthase | |
US6303771B1 (en) | Pth | |
US6537774B1 (en) | UPS (undecaprenyl diphosphate synthase | |
US6287807B1 (en) | MurF | |
EP0897007A2 (en) | MraY transferase | |
US6277595B1 (en) | FabZ | |
US6190881B1 (en) | Ribonucleotide diphosphate reductase, nrdF, of streptococcus pneumoniae | |
US6222026B1 (en) | Gcp | |
US6331411B1 (en) | TopA | |
EP0899329A2 (en) | DextranaseB gene from Streptococcus pneumoniae | |
US6361965B1 (en) | YfiI pseudouridine synthase | |
US6194170B1 (en) | MurF of Streptococcus pneumoniae | |
US6204014B1 (en) | DnaB | |
US6255075B1 (en) | Bira | |
US20020146790A1 (en) | MurF | |
US6222014B1 (en) | NrdE of staphylococcus aureus | |
US6432703B1 (en) | RATC from Streptococcus pneumoniae | |
US20030118992A1 (en) | ABC transporter | |
EP0890644A2 (en) | MurA gene from Staphylococcus aureus encoding DP-N-Acetylglucosamine enolpyruvyl transferase |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AL AU BA BB BG BR BZ CA CN CZ DZ EE GE GH GM HR HU ID IL IN IS JP KP KR LC LK LR LT LV MA MG MK MN MX MZ NO NZ PL RO SG SI SK SL TR TT TZ UA US UZ VN YU ZA |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2424987 Country of ref document: CA Ref document number: 10407028 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002534497 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000967340 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2000967340 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: JP |